Table 3 Paediatric antiretroviral therapy (ART) utilization among children on first-line ART at data transfer in TREAT Asia and IeDEA Southern Africa
TREAT Asia (N = 1164) | Â | IeDEA Southern Africa (N = 4412) | ||
|---|---|---|---|---|
Female, N (%) | 608 (52) | Â | Female, N (%) | 2179 (49) |
Most common regimens, N (%) | Â | Â | Most common regimens | Â |
AZT+3TC+NVP | 529 (46) | Â | d4T+3TC+EFV | 2154 (49) |
AZT+3TC+EFV | 299 (26) | Â | d4T+3TC+LPV/r | 979 (22) |
d4T+3TC+NVP | 183 (16) | Â | d4T+3TC+NVP | 671 (15) |
d4T+3TC+EFV | 53 (5) | Â | d4T+3TC+LPV/r+RTV | 128 (3) |
AZT+3TC+LPV/r | 33 (3) | Â | AZT+3TC+NVP | 119 (3) |
Median age, months (IQR) at start | 85 (47-119) | Â | Median age, months (IQR) at start | 56 (22-96) |
Median age, months (IQR) at data transfer | 129 (90-163) | Â | Median age, months (IQR) at data transfer | 79 (43-119) |
Median months (IQR) on regimen | 38 (20-58) | Â | Median months (IQR) on regimen | 19 (9-31) |